Overview

Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD

Status:
Unknown status
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
AECOPD increases the risk of VTE.VTE prevention is a long way to go for high-risk VTE patients in China.The incidence of AECOPD complicated with VTE in Asian population is high and the mortality rate is high.Rivaroxaban, a new oral anticoagulant, has been widely used in the treatment and prevention of VTE.However the question about the efficacy and safety of new oral anticoagulant compared with LMWHs for the prevention of symptomatic VTE and VTE-related death post-hospital discharge in high-risk AECOPD patients is still unknown. Thus this study is to evaluate if the prophylactic anticoagulation effect by Rivaroxaban is non-inferiority than Enoxaprine in high risk AECOPD and to evaluate the safety of using Rivaroxaban to prevent VTE in high risk AECOPD comparing with Enoxaprine.
Phase:
N/A
Details
Lead Sponsor:
Huashan Hospital
Treatments:
Enoxaparin
Rivaroxaban